|
KR102874080B1
(ko)
|
2016-07-07 |
2025-10-23 |
하워드 휴즈 메디컬 인스티튜트 |
변형된 리간드-게이팅 이온 채널 및 사용 방법
|
|
US12459965B2
(en)
|
2017-10-09 |
2025-11-04 |
Compass Pathfinder Limited |
Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
|
|
GB2571696B
(en)
|
2017-10-09 |
2020-05-27 |
Compass Pathways Ltd |
Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
|
|
JP2021502101A
(ja)
|
2017-11-10 |
2021-01-28 |
ハワード ヒューズ メディカル インスティチュート |
修飾されたリガンド依存性イオンチャネルおよび使用の方法
|
|
EP4219498A1
(en)
*
|
2019-03-07 |
2023-08-02 |
Arbormentis LLC |
Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic / psychotomimetic dosages and formulations
|
|
KR20220009954A
(ko)
|
2019-04-17 |
2022-01-25 |
컴퍼스 패쓰파인더 리미티드 |
신경인지 장애, 만성 통증을 치료하고 염증을 감소시키는 방법
|
|
EP4003395A4
(en)
*
|
2019-07-23 |
2023-07-19 |
Caamtech, Inc. |
COMPOSITIONS WITH TOAD SECRETION COMPOUNDS
|
|
CN114787363A
(zh)
|
2019-10-01 |
2022-07-22 |
恩派瑞安神经科学公司 |
对真菌进行遗传工程化以调节色胺表达
|
|
CN114650809A
(zh)
|
2019-10-03 |
2022-06-21 |
斯塔顿治疗公司 |
屈大麻酚的透皮递送
|
|
US12409131B2
(en)
|
2019-10-03 |
2025-09-09 |
Pike Therapeutics Usa, Inc. |
Transdermal delivery of dronabinol
|
|
US12016829B2
(en)
|
2019-10-11 |
2024-06-25 |
Pike Therapeutics Inc. |
Pharmaceutical composition and method for treating seizure disorders
|
|
CA3155176A1
(en)
|
2019-10-11 |
2021-04-15 |
Pike Therapeutics, Inc., 1219014 B.C. Ltd. |
Transdermal compositions comprising cannabidiol (cbd) for use in the treatment of seizure disorders
|
|
CA3155181A1
(en)
|
2019-10-14 |
2021-04-22 |
Pike Therapeutics, Inc., 1219014 B.C. Ltd. |
Transdermal delivery of cannabidiol
|
|
US12268699B2
(en)
|
2019-10-14 |
2025-04-08 |
Pike Therapeutics Inc. |
Transdermal delivery of tetrahydrocannabinol
|
|
US12121617B2
(en)
|
2019-10-14 |
2024-10-22 |
Pike Therapeutics Inc. |
Transdermal delivery of cannabidiol
|
|
WO2021072530A1
(en)
*
|
2019-10-15 |
2021-04-22 |
Tassili Life Sciences, Corp. |
Controlled release formulations of psilocybe-derived agents and method for their use, and methods and compositions for threating mild traumatic brain injury with post traumatic stress disorder.
|
|
CA3160793A1
(en)
*
|
2019-12-04 |
2021-06-10 |
Neonmind Biosciences Inc. |
Use of psilocin, psilocybin or analogs thereof in weight loss, treatment of obesity and compulsive eating disorder
|
|
US20210220336A1
(en)
*
|
2020-01-22 |
2021-07-22 |
Clexio Biosciences Ltd. |
Topical detomidine formulations
|
|
PH12022551981A1
(en)
|
2020-02-04 |
2023-10-16 |
Mindset Pharma Inc |
Psilocin derivatives as serotonergic psychedelic agents for the treatment of cns disorders
|
|
MX2022009528A
(es)
|
2020-02-04 |
2022-11-14 |
Mindset Pharma Inc |
Derivados de 3-pirrolidina-indol como agentes psicodélicos serotoninérgicos para el tratamiento de trastornos del snc.
|
|
WO2021207824A1
(en)
*
|
2020-04-17 |
2021-10-21 |
Revive Therapeutics Ltd. |
Use of psilocybin in the treatment of neurological brain injury and migraines
|
|
IL297912A
(en)
|
2020-05-05 |
2023-01-01 |
Univ Basel |
Mdma treatment to enhance acute emotional effects profile of lsd, psilocybin or other psychedelics
|
|
AU2021268204A1
(en)
|
2020-05-08 |
2022-12-08 |
Psilera Inc. |
Novel compositions of matter and pharmaceutical compositions
|
|
KR20240096817A
(ko)
|
2020-05-19 |
2024-06-26 |
사이빈 아이알엘 리미티드 |
중수소화된 트립타민 유도체 및 사용 방법
|
|
WO2021243460A1
(en)
*
|
2020-06-03 |
2021-12-09 |
Neonmind Biosciences Inc. |
Method for weight loss with therapy
|
|
CA3186958A1
(en)
*
|
2020-07-29 |
2022-02-03 |
Judith BLUMSTOCK |
Extended release 5-ht receptor agonists for neurological conditions
|
|
WO2022051578A1
(en)
*
|
2020-09-03 |
2022-03-10 |
Yale University |
Psilocybin in patients with obsessive-compulsive disorder
|
|
US20230364115A1
(en)
*
|
2020-10-01 |
2023-11-16 |
Mydecine Innovations Group Inc. |
Novel psychedelic compositions, delivery systems and therapeutic uses thereof
|
|
CA3197488A1
(en)
*
|
2020-10-12 |
2022-04-21 |
Goodcap Pharmaceuticals Ltd. |
Compositions for reducing inflammation to improve or maintain mental or physical health
|
|
US20230398234A1
(en)
*
|
2020-10-28 |
2023-12-14 |
Mydecine Innovations Group Inc. |
Novel fungal compoind formulations and their therapeutic methods of use
|
|
US12029718B2
(en)
|
2021-11-09 |
2024-07-09 |
Cct Sciences, Llc |
Process for production of essentially pure delta-9-tetrahydrocannabinol
|
|
EP4251139A2
(en)
*
|
2020-11-30 |
2023-10-04 |
Wesana Health Inc. |
Compositions and methods for treating migraine
|
|
US20240050454A1
(en)
*
|
2020-11-30 |
2024-02-15 |
Jeffrey Jewell |
Compositions and Methods For Treating Neurological Conditions
|
|
US12343328B2
(en)
|
2020-12-09 |
2025-07-01 |
Caamtech, Inc. |
Dialkyl tryptamines and their therapeutic uses
|
|
CA3113240C
(en)
|
2020-12-28 |
2023-09-05 |
Psilo Scientific Ltd. |
Transmucosal psychoactive alkaloid composition and preparation thereof
|
|
EP4126857A1
(en)
|
2021-01-15 |
2023-02-08 |
Beckley Psytech Limited |
Ergoline analogues
|
|
US12534441B2
(en)
|
2021-01-15 |
2026-01-27 |
Beckley Psytech Limited |
Tryptamine analogues
|
|
US11312684B1
(en)
|
2021-02-10 |
2022-04-26 |
Eleusis Therapeutics Us, Inc. |
Pharmaceutically acceptable salts of psilocin and uses thereof
|
|
US20220265601A1
(en)
*
|
2021-02-10 |
2022-08-25 |
David Alan Heldreth, JR. |
Methods of use and formulations of allosteric modulators of the serotonin, dopamine and other receptor systems for medical, recreational, religious, research and other uses.
|
|
US20220273628A1
(en)
*
|
2021-02-19 |
2022-09-01 |
Universitätsspital Basel |
Effects of lysergic acid diethylamide (lsd) and of lsd analogs to assist psychotherapy for generalized anxiety disorder or other anxiety not related to life-threatening illness
|
|
US20220370413A1
(en)
*
|
2021-03-06 |
2022-11-24 |
Mind Medicine, Inc. |
Formulations of psilocin that have enhanced stability
|
|
WO2022189855A1
(en)
*
|
2021-03-08 |
2022-09-15 |
Diamond Therapeutics Inc. |
5-ht receptor agonist titration
|
|
WO2022204323A1
(en)
*
|
2021-03-24 |
2022-09-29 |
The Trustees Of Columbia University In The City Of New York |
Non-hallucinogenic ariadne analogs for treatment of neurological and psychiatric disorders
|
|
EP4312995A1
(en)
*
|
2021-03-30 |
2024-02-07 |
COMPASS Pathfinder Limited |
Psilocybin compositions, methods of making and methods of using the same
|
|
US20230026731A1
(en)
*
|
2021-03-31 |
2023-01-26 |
Mycrodose Therapeutics Inc. |
Transdermal system, formulation, and method for the therapeutic administration of a psychedelic agent
|
|
WO2022221554A2
(en)
*
|
2021-04-16 |
2022-10-20 |
Callitas Health Inc. |
Compositions and methods for delivery of psilocin and prodrugs thereof
|
|
WO2022221942A1
(en)
*
|
2021-04-19 |
2022-10-27 |
Betterlife Pharma Inc. |
Prevention of drug diversion
|
|
CN117355302A
(zh)
*
|
2021-04-30 |
2024-01-05 |
思维医学股份有限公司 |
Lsd盐晶体形式
|
|
EP4333979A4
(en)
*
|
2021-05-03 |
2025-01-15 |
Mind Medicine, Inc. |
Method of titrating dose of psychedelics
|
|
US20220354862A1
(en)
*
|
2021-05-04 |
2022-11-10 |
Mind Medicine, Inc. |
Liposome delivery of psychedelics
|
|
EP4351539B1
(en)
*
|
2021-06-07 |
2026-04-22 |
University of Mississippi |
Methods for the pulsed delivery of bioactive agents
|
|
US11801256B2
(en)
|
2021-06-08 |
2023-10-31 |
Universitätsspital Basel |
Antidepressant-psilocybin co-treatment to assist psychotherapy
|
|
GB202109023D0
(en)
*
|
2021-06-23 |
2021-08-04 |
Ldn Pharma Ltd |
Compositions comprising an agonist of 5-hydroxytryptamine (5-ht) receptor subtype 3
|
|
WO2022272176A1
(en)
*
|
2021-06-25 |
2022-12-29 |
Synaptive Therapeutics, Llc |
Psilocybin analogs for treating psychological disorders
|
|
JP2024529727A
(ja)
|
2021-08-19 |
2024-08-08 |
マインド メディシン， インコーポレイテッド |
治療適用のためのｄ－リゼルグ酸ジエチルアミドの凍結乾燥された口腔内崩壊錠製剤
|
|
US12492178B2
(en)
|
2021-09-01 |
2025-12-09 |
Empathbio, Inc. |
Stable polymorph of R-MDMA HCl
|
|
IL326048A
(en)
*
|
2021-09-03 |
2026-03-01 |
Alexander Shulgin Res Institute Inc |
Asymmetric allyl tryptamines
|
|
EP4408412A4
(en)
*
|
2021-09-30 |
2025-07-16 |
ATAI Life Sciences AG |
COMPOSITIONS AND METHODS FOR TREATING HEADACHES
|
|
EP4429672A4
(en)
*
|
2021-11-12 |
2025-04-30 |
Terran Biosciences Inc. |
PSILOCYBIN AND O-ACETYLPSILOCIN, SALTS AND SOLID FORMS THEREOF
|
|
WO2023086962A1
(en)
*
|
2021-11-12 |
2023-05-19 |
Terran Biosciences Inc. |
Psilocybin and o-acetylpsilocin, salts and solid state forms thereof
|
|
US11912680B2
(en)
|
2021-12-28 |
2024-02-27 |
Empathbio, Inc. |
Nitric oxide releasing prodrugs of MDA and MDMA
|
|
JP2024545787A
(ja)
|
2021-12-30 |
2024-12-11 |
アタイ セラピューティクス， インコーポレイテッド |
一酸化窒素送達剤としてのジメチルトリプタミン類似体
|
|
EP4457336A4
(en)
|
2021-12-31 |
2026-01-14 |
Empyrean Neuroscience Inc |
ORGANISMS GENETICALLY MODIFIED TO PRODUCE PSYCHOTROPIC ALKALOIDS
|
|
WO2023137094A1
(en)
*
|
2022-01-12 |
2023-07-20 |
Eleusis Therapeutics Us, Inc. |
Psilocin benzoate formulation for intravenous infusion
|
|
WO2023168023A1
(en)
|
2022-03-04 |
2023-09-07 |
Reset Pharmaceuticals, Inc. |
Co-crystals or salts comprising psilocin
|
|
WO2023183618A1
(en)
*
|
2022-03-25 |
2023-09-28 |
Ojai Energetics Pbc |
Psychedelic compositions and methods for forming the same
|
|
US20240002463A1
(en)
*
|
2022-04-27 |
2024-01-04 |
Howard Hughes Medical Institute |
Chemogenetic receptors and methods of making and using
|
|
EP4522164A1
(en)
*
|
2022-05-13 |
2025-03-19 |
Reset Pharmaceuticals, Inc. |
Administration of a psychedelic compound by intramuscular injection
|
|
CA3247344A1
(en)
|
2022-06-09 |
2023-12-14 |
Diamond Therapeutics Inc. |
AMORPHIC PSILOCYBIN (A-POLYMORPHIC)
|
|
WO2023248222A1
(en)
*
|
2022-06-21 |
2023-12-28 |
Technion Research & Development Foundation Limited |
5-ht2c receptor modulating agents for the treatment of neurodegenerative, mental, cognitive and autoimmune cns disorders
|
|
US20240000795A1
(en)
*
|
2022-06-30 |
2024-01-04 |
Terran Biosciences Inc. |
Methods and compositions relating to controlling psychedelic effects with serotonin receptor modulators
|
|
US12344583B2
(en)
|
2022-07-12 |
2025-07-01 |
Lobe Sciences Ltd. |
Solid psilocin salts
|
|
CA3261867A1
(en)
*
|
2022-07-12 |
2024-01-18 |
Cynaptec Pharmaceuticals, Inc. |
PREPARATION OF STABLE PSILOCIN SALTS, ESTERS AND CONJUGATES AND THEIR USES
|
|
US20260000693A1
(en)
*
|
2022-07-19 |
2026-01-01 |
Lobe Sciences Ltd. |
Serotonergic psychedelic agent for treating selective mutism
|
|
US12264131B2
(en)
|
2022-08-19 |
2025-04-01 |
Beckley Psytech Limited |
Pharmaceutically acceptable salts and compositions thereof
|
|
WO2024079648A1
(en)
*
|
2022-10-11 |
2024-04-18 |
Sintalica S.R.L. |
Delivery system for the controlled release of psychedelic compound, pharmaceutical composition and uses thereof
|
|
WO2024151625A1
(en)
*
|
2023-01-10 |
2024-07-18 |
Georgetown University |
Non-toxic plga compositions and methods of making and using same
|
|
CN121358470A
(zh)
*
|
2023-02-23 |
2026-01-16 |
布莱特西德公司 |
用于调节g蛋白偶联受体的组合物和方法
|
|
US12246005B2
(en)
|
2023-06-13 |
2025-03-11 |
Beckley Psytech Limited |
5-methoxy-n,n-dimethyltryptamine (5-MeO-DMT) formulations
|
|
WO2025010308A2
(en)
*
|
2023-07-03 |
2025-01-09 |
Empathbio, Inc. |
Mdma enantiomer compositions and methods for modulating aggression response
|
|
WO2025024400A2
(en)
*
|
2023-07-21 |
2025-01-30 |
2A Biosciences, Inc. |
Substituted tryptamines and uses thereof
|
|
WO2025040932A1
(en)
*
|
2023-08-21 |
2025-02-27 |
Nechama Golan |
Fully curing all mental diseases with the use of d-lysergic acid amide in different doses and time of treatment
|
|
WO2026068690A1
(en)
*
|
2024-09-27 |
2026-04-02 |
Medichem, S.A. |
Quetiapine long-acting injection
|